Zydus Lifesciences Shares Gain on Robust Q4 Results with Buyback Announcement Clorox CLX Reports Strong Q1 2026 Revenue NA EPS Beats Trevi Therapeutics TRVI Q1 2026 Disappoints EPS 009 Below 008 Views NexPoint NXRT Delivers Q1 2026 Beat EPS 027 vs 037 Expected